Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CLIO-8221 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on CLIO-8221, a putative antibody-drug conjugate (ADC) targeting ERBB2 (HER2) with TOP1 and ATR inhibitor dual payloads (Dec 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CLIO-8221 | CLIO 8221|CLIO8221 | HER2 (ERBB2) Antibody-Drug Conjugate 36 | Limited information is currently available on CLIO-8221, a putative antibody-drug conjugate (ADC) targeting ERBB2 (HER2) with TOP1 and ATR inhibitor dual payloads (Dec 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07300943 | Phase Ib/II | CLIO-8221 | Study in Advanced Solid Tumor Patients | Not yet recruiting | USA | AUS | 0 |